Difference between revisions of "Healthcare AI Use Cases"

From PatientRecovery
Jump to: navigation, search
Line 15: Line 15:
  
 
Providers & ACOs <br>
 
Providers & ACOs <br>
 +
* [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news '''Appointment No-Shows''' - Predict patients most likely to miss appointments]
 +
* [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news Predict patients most likely to acquire infections like sepsis]
 +
* [https://news.mit.edu/2020/closedloop-ai-predictive-health-care-0619?utm_source=miragenews&utm_medium=miragenews&utm_campaign=news Predict patients most likely to benefit from periodic check ups]
 +
* Leakage - Network Integrity - Out of Network
 
* Total Risk:  Who will be my most expensive patients this year
 
* Total Risk:  Who will be my most expensive patients this year
 
* ED Over-Utilization:  Which of my patients would most benefit from establishing a relationship with a primary care provider?
 
* ED Over-Utilization:  Which of my patients would most benefit from establishing a relationship with a primary care provider?

Revision as of 11:26, 10 July 2020

ClosedLoop AI Use Cases

Hospitals

Health Insurers


Providers & ACOs

Payers and Health Plans

  • Trend: Which members are likely to see large increases in their overall health risk over the next three to six months?
  • Readmissions: Which members are most likely to be readmitted to the hospital?
  • Medication Adherence: Which members are most likely to be noncompliant with medication plans?
  • Palliative Care: Which members are most likely to benefit from discussions with a palliative care specialist?
  • ED Over-Utilization: Which members are most likely to benefit from establishing a relationship with a primary care provider?
  • Disenrollment: Which members will most likely to disenroll?
  • Fraud: How do new data sources allow health plans to spot fraud sooner?
  • Payment Integrity: How can AI help ensure proper reimbursement?

Pharma & Life Science

  • Biomarkers: Which patients will have an increased success rate based on biological factors?
  • Drug-Combinations: Which drug combinations are most likely to be successful?
  • Segmentation: Which groups of patients respond differently to treatment?
  • Strategy: Which subpopulations should be included/excluded based off of predicted success rates?
  • Responsive: Which patients are responding to treatment?
  • Events: Which patients are most likely to experience adverse reactions?
  • Effectiveness: How will clinical trial results translate into real world effectiveness?
  • Value: What improvement in outcomes will a new treatment generate over existing therapies?
  • Switching: Which factors are most relevant in understanding which patients switch drugs?
  • Marketing: Which physicians can we market to?


Other